BR112018067946A8 - Formulações tópicas contendo ciclosporina e usos das mesmas - Google Patents

Formulações tópicas contendo ciclosporina e usos das mesmas

Info

Publication number
BR112018067946A8
BR112018067946A8 BR112018067946A BR112018067946A BR112018067946A8 BR 112018067946 A8 BR112018067946 A8 BR 112018067946A8 BR 112018067946 A BR112018067946 A BR 112018067946A BR 112018067946 A BR112018067946 A BR 112018067946A BR 112018067946 A8 BR112018067946 A8 BR 112018067946A8
Authority
BR
Brazil
Prior art keywords
formulations
formulations containing
topical formulations
containing cyclosporine
cyclosporine
Prior art date
Application number
BR112018067946A
Other languages
English (en)
Other versions
BR112018067946A2 (pt
Inventor
L Weiss Sidney
K Mitra Ashim
J Mcnally Eugene
Original Assignee
Sun Pharma Global Fze
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59744365&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112018067946(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharma Global Fze, Sun Pharmaceutical Ind Ltd filed Critical Sun Pharma Global Fze
Publication of BR112018067946A2 publication Critical patent/BR112018067946A2/pt
Publication of BR112018067946A8 publication Critical patent/BR112018067946A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A presente invenção refere-se a formulações para formulações oftálmicas tópicas contendo 0,087-0,093% em peso de ciclosporina, e métodos de fabricação e uso de tais formulações. Em alguns aspectos e modalidades, as formulações podem incluir um polioxil lipídeo ou ácido graxo, e/ou um álcool polialcoxilado e podem incluir nanomicelas. Também incluídos aqui são métodos de tratamento ou prevenção de doenças ou condições, tais como doenças ou condições oculares.
BR112018067946A 2016-02-29 2017-02-28 Formulações tópicas contendo ciclosporina e usos das mesmas BR112018067946A8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662301576P 2016-02-29 2016-02-29
US201662302058P 2016-03-01 2016-03-01
US201662302730P 2016-03-02 2016-03-02
US201662311177P 2016-03-21 2016-03-21
PCT/US2017/020008 WO2017151657A1 (en) 2016-02-29 2017-02-28 Topical cyclosporine-containing formulations and uses thereof

Publications (2)

Publication Number Publication Date
BR112018067946A2 BR112018067946A2 (pt) 2019-01-15
BR112018067946A8 true BR112018067946A8 (pt) 2022-11-08

Family

ID=59744365

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018067946A BR112018067946A8 (pt) 2016-02-29 2017-02-28 Formulações tópicas contendo ciclosporina e usos das mesmas

Country Status (20)

Country Link
US (4) US10918694B2 (pt)
EP (2) EP3423076B1 (pt)
JP (1) JP7072517B2 (pt)
KR (1) KR20180117661A (pt)
CN (1) CN109843316A (pt)
AU (2) AU2017227585C1 (pt)
BR (1) BR112018067946A8 (pt)
CA (1) CA3015626A1 (pt)
DK (1) DK3423076T3 (pt)
FI (1) FI3423076T3 (pt)
IL (1) IL268056A (pt)
MX (1) MX2018010395A (pt)
NZ (1) NZ755442A (pt)
PL (1) PL3423076T3 (pt)
PT (1) PT3423076T (pt)
RU (1) RU2747455C2 (pt)
SA (1) SA519410114B1 (pt)
SG (1) SG11201906729RA (pt)
WO (1) WO2017151657A1 (pt)
ZA (1) ZA201904704B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2914472C (en) 2012-08-24 2019-09-03 Ashim K. Mitra Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
ES2974821T3 (es) 2015-11-10 2024-07-01 Sun Pharmaceutical Ind Ltd Formulaciones tópicas y usos de las mismas
BR112018067946A8 (pt) 2016-02-29 2022-11-08 Sun Pharma Global Fze Formulações tópicas contendo ciclosporina e usos das mesmas
CN112957450A (zh) * 2019-12-20 2021-06-15 艾棣维欣(苏州)生物制药有限公司 一种难溶性药物的水溶液及其制备方法
AU2022295164A1 (en) 2021-06-14 2024-01-25 Sun Pharmaceutical Industries Limited Cyclosporine formulations for use in patients undergoing cataract surgery
MX2024002234A (es) 2021-08-20 2024-04-17 Sun Pharmaceutical Ind Ltd Formulación oftalmológica de ciclosporina estable y proceso de fabricación de esta.
WO2024042550A1 (en) * 2022-08-25 2024-02-29 Sentiss Pharma Private Limited Ophthalmic combination composition
WO2024098043A2 (en) * 2022-11-04 2024-05-10 Qlaris Bio, Inc. Topical ocular delivery of cromakalim

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0642332T3 (da) 1992-05-13 1997-06-16 Sandoz Ltd Ophthalmiske præparater indeholdende cyclosporin
NZ247516A (en) 1993-04-28 1995-02-24 Bernard Charles Sherman Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
US5484597A (en) 1993-07-30 1996-01-16 Chesebrough-Pond's Usa Co. Clear hydroalcholic cosmetic microemulsions
NZ280689A (en) 1995-12-15 1997-08-22 Bernard Charles Sherma Sherman Pharmaceutical composition comprising a cyclosporipharmaceutical composition comprising a cyclosporin; a tocol, tocopherol or tocotrienol; and propylen; a tocol, tocopherol or tocotrienol; and propylene carbonate or polyethylene glycol ne carbonate or polyethylene glycol
MX9701946A (es) 1997-03-14 1998-04-30 Arturo Jimenez Bayardo Solucion oftalmica transportadora.
US7678836B2 (en) 1999-11-04 2010-03-16 Fxs Ventures, Llc Method for rendering a contact lens wettable
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US20030176356A1 (en) 2001-04-24 2003-09-18 University Of North Texas Health Science Center Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma
BR0213661A (pt) 2001-10-19 2004-10-26 Isotechnika Inc Pré-concentrado de microemulsão e método para seu preparo, formulação farmacêutica e método para seu preparo, método para produzir imuno, supressão, método para aumentar os efeitos imuno supressores de isatx247, uso de formulação farmacêutica
WO2004069181A2 (en) 2003-02-03 2004-08-19 Pharmacia Corporation Composition for the treatment of intraocular pressure
JP2004238346A (ja) 2003-02-07 2004-08-26 Shiono Chemical Co Ltd トラニラストの安定な水溶液製剤
AU2003228126A1 (en) 2003-05-02 2004-11-23 Arturo Jimenez Bayardo Method of preparing an aqueous solution of cyclosporin-a and resulting aqueous solution
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
ATE412400T1 (de) 2004-11-09 2008-11-15 Novagali Pharma Sa Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
WO2006132342A1 (ja) 2005-06-09 2006-12-14 Santen Pharmaceutical Co., Ltd. ロフルミラスト点眼液
NZ562109A (en) 2005-06-16 2011-03-31 Myrexis Inc Pharmaceutical compositions containing substituted (4-Phenyl)-methyl-(quinazolin-4-yl)-amine compounds, uses thereof, and methods of preparing the same
US20070015691A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
PL1904056T3 (pl) 2005-07-18 2009-09-30 Minu Llc Zastosowanie makrolidu do przywracania czucia rogówkowego
US10137083B2 (en) 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
EP2011516A4 (en) 2006-04-24 2010-06-23 Nanocarrier Co Ltd PROCESS FOR THE PRODUCTION OF A POLYMERIC MICELLE THAT CONTAINS A CHEMICAL PRODUCT OF LOW MOLECULAR WEIGHT ENCAPSULATED IN IT
WO2007136134A1 (ja) 2006-05-23 2007-11-29 Nanocarrier Co., Ltd. 疎水性薬物内包ポリマーミセルの製造方法
KR101363498B1 (ko) 2006-07-18 2014-02-14 나노캬리아 가부시키가이샤 생리활성 폴리펩티드 또는 단백질 내포 고분자 폴리머 미셀및 그 제조방법
US20100310462A1 (en) 2007-04-18 2010-12-09 Biochromix Ab Binding of pathological forms of proteins using conjugated polyelectrolytes
US8512687B2 (en) 2007-07-09 2013-08-20 Novagali Pharma Sa Oil in water emulsion comprising NSAIDs and quaternary ammonium halides
ES2511840T3 (es) 2007-08-29 2014-10-23 Wakamoto Pharmaceutical Co., Ltd. Composición farmacéutica acuosa que contiene latanoprost
MX2007011165A (es) 2007-09-12 2009-03-11 Arturo Jimenez Bayardo Composición farmacéutica estable de timolol, dorzolamida y brimonidina.
CN101918019B (zh) 2007-10-08 2014-11-26 奥里尼亚制药有限公司 包含钙调神经磷酸酶抑制剂或mTOR抑制剂的眼科组合物
MX2010007295A (es) 2008-01-04 2010-10-11 Alcon Pharmaceuticals Ltd Composiciones acuosas estables de ciclosporina.
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
KR20110010788A (ko) 2008-05-28 2011-02-07 알콘 리서치, 리미티드 자기보존 에멀젼
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
BRPI1010175A2 (pt) 2009-06-02 2016-03-29 Keller Brian Charles "composição química que inclui um conjugado de lipídio-peg e lipossoma"
AU2010259184B2 (en) 2009-06-09 2015-08-13 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
CA2773597A1 (en) 2009-09-17 2011-03-24 Senju Pharmaceutical Co., Ltd. Latanoprost-containing aqueous eye drops and method for inhibiting adsorption of latanoprost to resin
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
EP2538965B1 (en) 2010-02-25 2017-04-12 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
KR20130139748A (ko) 2010-05-07 2013-12-23 썬 파마 어드밴스트 리서치 컴패니 리미티드 신규 안과용 조성물
US20130065888A1 (en) 2011-08-15 2013-03-14 Biserka Cetina-Cizmek Ophthalmic formulations and processes for their preparation
US9278132B2 (en) 2012-02-13 2016-03-08 Bausch & Lomb Incorporated Ophthalmic pharmaceutical compositions and methods of making and using same
KR101211902B1 (ko) * 2012-04-30 2012-12-13 주식회사 휴온스 사이클로스포린 함유 무자극성 나노에멀젼 안약 조성물
AU2013257830A1 (en) 2012-05-11 2014-11-20 Cipla Limited Pharmaceutical composition
CA2914472C (en) 2012-08-24 2019-09-03 Ashim K. Mitra Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
WO2014126997A1 (en) 2013-02-13 2014-08-21 The Research Foundation For The State University Of New York Glaucoma treatment
AU2015264181A1 (en) 2014-05-23 2016-12-01 Ocular Technologies Sarl Topical formulations and uses thereof
US20150352176A1 (en) * 2014-06-06 2015-12-10 Newport Research, Inc. Oil-free and fat-free aqueous suspensions of cyclosporin
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016178881A1 (en) * 2015-05-04 2016-11-10 Ocular Technologies Sarl Topical formulations and uses thereof
ES2974821T3 (es) 2015-11-10 2024-07-01 Sun Pharmaceutical Ind Ltd Formulaciones tópicas y usos de las mismas
US20180333352A1 (en) 2015-11-12 2018-11-22 Sun Pharma Global Fze Topical formulations and uses thereof
BR112018067946A8 (pt) 2016-02-29 2022-11-08 Sun Pharma Global Fze Formulações tópicas contendo ciclosporina e usos das mesmas
WO2017152129A2 (en) 2016-03-03 2017-09-08 Ocular Technologies Sarl Treatment of glaucoma and/or retinal diseases and formulations useful therefore

Also Published As

Publication number Publication date
US20240197818A1 (en) 2024-06-20
US20190060397A1 (en) 2019-02-28
CA3015626A1 (en) 2017-09-08
PT3423076T (pt) 2024-07-01
PL3423076T3 (pl) 2024-08-19
ZA201904704B (en) 2022-10-26
RU2019130403A3 (pt) 2021-03-26
JP2022110054A (ja) 2022-07-28
RU2019130403A (ru) 2021-03-26
DK3423076T3 (da) 2024-07-08
AU2022203135A1 (en) 2022-06-02
EP3423076B1 (en) 2024-04-17
US11951153B2 (en) 2024-04-09
JP2019507154A (ja) 2019-03-14
US10918694B2 (en) 2021-02-16
US20230083458A1 (en) 2023-03-16
EP4410312A2 (en) 2024-08-07
SG11201906729RA (en) 2019-08-27
AU2017227585A1 (en) 2018-10-18
CN109843316A (zh) 2019-06-04
SA519410114B1 (ar) 2024-02-11
IL268056A (en) 2019-08-29
AU2017227585C1 (en) 2022-05-26
AU2017227585B2 (en) 2022-02-17
RU2747455C2 (ru) 2021-05-05
US20210145924A1 (en) 2021-05-20
MX2018010395A (es) 2018-11-29
KR20180117661A (ko) 2018-10-29
NZ755442A (en) 2023-04-28
BR112018067946A2 (pt) 2019-01-15
EP3423076A4 (en) 2019-11-27
FI3423076T3 (fi) 2024-06-24
JP7072517B2 (ja) 2022-05-20
EP3423076A1 (en) 2019-01-09
WO2017151657A1 (en) 2017-09-08

Similar Documents

Publication Publication Date Title
BR112018067946A8 (pt) Formulações tópicas contendo ciclosporina e usos das mesmas
CL2018001089A1 (es) Sales de valbenazina y polimorfos de las mismas.
CL2019002255A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas.
NI201900041A (es) 1, 2, 4-triazolonas 2, 4, 5-trisustituidas
CL2017001296A1 (es) Anticuerpos contra cd73 y sus usos
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201792047A1 (ru) Новые соединения
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
BR112018072946A2 (pt) proteínas de fusão a gdf15 e usos das mesmas
MX361858B (es) Formulación oftálmica de lípido polioxilo o de ácido graso polioxilo y tratamiento de padecimientos oculares.
BR112016027871A2 (pt) composição para melhorar a memória, a função de aprendizado e/ou função cognitiva
CO2017009433A2 (es) Proteínas específicas para pioverdina y pioquelina
BR112016013109A2 (pt) anticorpos de anti-siglec-8 e métodos de seu uso
BR112018001232A2 (pt) pd-l1 que expressa células-tronco hematopoéticas e usos
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
BR112016022318A2 (pt) método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
CO2019002889A2 (es) Tratamientos de combinación que comprenden la administración de imidazopirazinonas
BR112018017031A2 (pt) formulações de antagonista de il-6 e usos das mesmas
BR112019004353A2 (pt) métodos e vetores para tratar distúrbios do cns
EA201692279A1 (ru) Способ уменьшения иммуногенности белка и пептида
AR101735A1 (es) Anticuerpo terapéutico anti-bdnf (factor neurotrófico derivado del cerebro)
EA201891710A1 (ru) Терапевтические соединения
BR112017007428A2 (pt) composições de éster de ácido graxo e ácidos graxos autocomnizantes e suas utilizações no tratamento de estados da doença
CL2021002483A1 (es) Compuestos y composiciones como moduladores de la señalización tlr

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25A Requested transfer of rights approved

Owner name: SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN)

B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122022024664-8 PROTOCOLO 870220111978 EM 01/12/2022 17:52.